Emergent Biosolutions
EBS
162 hedge funds and large institutions have $141M invested in Emergent Biosolutions in 2023 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 47 increasing their positions, 54 reducing their positions, and 46 closing their positions.
11.13% less ownership
Funds ownership: 90.62% → 79.49% (-11%)
11% less funds holding
Funds holding: 183 → 162 (-21)
13% less repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 54
43% less first-time investments, than exits
New positions opened: 26 | Existing positions closed: 46
46% less call options, than puts
Call options by funds: $314K | Put options by funds: $580K
58% less capital invested
Capital invested by funds: $336M → $141M (-$195M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$13.2M |
| 2 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$7.17M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$3.21M |
| 4 |
Squarepoint
New York
|
+$2.99M |
| 5 |
Jane Street
New York
|
+$2.92M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$31.4M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.4M |
| 3 |
BlackRock
New York
|
-$4.41M |
| 4 |
Rafferty Asset Management
New York
|
-$4.27M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.81M |
EBS Hedge Fund Activity: Q3 2023 in Review
162 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Emergent Biosolutions (EBS) for Q3 2023, worth a combined $141M — down 58% from $336M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of EBS and 26 opened new positions — a net loss of 20 holders — while 54 trimmed existing stakes and 47 added.
The largest buyer was Millennium Management, adding an estimated $13.2M. The largest seller was State Street, cutting an estimated $31.4M.
- 162 institutional investors held Emergent Biosolutions (EBS) as of Q3 2023, down from 183 in Q2 2023.
- Funds reported $141M of Emergent Biosolutions stock for Q3 2023, down 58% quarter-over-quarter.
- 26 funds opened new Emergent Biosolutions positions in Q3 2023 and 46 closed out, a net change of -20 holders.
- The largest Emergent Biosolutions buyer in Q3 2023 was Millennium Management, an estimated $13.2M added.
- The largest Emergent Biosolutions seller in Q3 2023 was State Street, an estimated $31.4M sold.
Based on aggregated 13F filings for Q3 2023.